Videos

Important factors to consider when classifying patients’ risk status during the diagnosis of an inflammatory bowel disease and the impact of risk assessment as it relates to treatment selection based on the current therapeutic algorithm.

Norman Lepor, MD, FACC, FAHA, FSCAI, challenges the use of ezetimibe before a PCSK9 inhibitor in a population with no acute coronary syndrome.

Key opinion leaders in cardiology share their perspectives on using inclisiran post FDA approval within the current treatment landscape based on guidelines.

A discussion on ease of access for dupilumab for the treatment of atopic dermatitis including the process for approval and coverage.

Examining the potential role for biologic, dupilumab, in the treatment of moderate to severe atopic dermatitis.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.

Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.

Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.

Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.

Dr. Jennifer Payne discusses how the events of the last year has impacted her patients and what needs to happen to improve mental health care in the future.

Insight on the screening and monitoring for red blood cell transfusion for the management of sickle cell disease.

Wally Smith, MD, discusses L-glutamine in the treatment of SCD.

Henry Nasrallah, MD, compares the European Guidelines and United States Guidelines; the panel discusses guidelines currently in place for psychiatric patients.

Joe Avelino, RN, BSN, MHSA, CPHQ, defines a hospital versus an institution; and Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the lack of guideline-supported protocols for patients

Experts share insights on how they have utilized Prescription Monitoring Programs to combat the opioid crisis and improve the safety of prescribed opioids.

Experts share approaches to normalize conversations about naloxone with patients, as well as share important considerations for maximizing naloxone education.

ABX464 is being tested for numerous indications, including ulcerative colitis.

Common organs impacted by inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis and recommendations for assessing disease severity when diagnosing patients.

Marla Dubinsky, MD, of the Icahn School of Medicine at Mount Sinai, describes the progressive nature and differences in the presentation of inflammatory bowel disease symptoms in pediatric and adult patients.

Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.

Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

A review of the safety and efficacy of systemic agents such as methotrexate, azathioprine, and cyclosporine in patients with severe, persistent atopic dermatitis.

Experts in the management of atopic dermatitis review the safety and efficacy of topical calcineurin inhibitors and topical PDE4 inhibitors.

Contraindications for clinicians to keep in mind when administering sacubitril/valsartan therapy, and an examination of target dose for therapies in heart failure with reduced ejection fraction.